Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines.

< BACK TO ARCHIVE


2021 Dec 31


Saudi Pharm J


http://www.ncbi.nlm.nih.gov/pubmed/35002372?dopt=Abstract

Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines.

Authors

Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines.
Albalawi OM, Alomran MI, Alsagri GM, Althunian TA, Alshammari TM
Saudi Pharm J. 2021 Dec 31.
PMID: 35002372.

Abstract

Since December 2020, three COVID-19 vaccines have been authorized in the United States (U.S.) and were proceeded by large immunization programs. The aim of this study was to characterize the U.S. post-marketing safety (PMS) profiles of these vaccines with an in-depth analysis of mortality data.
Read This Paper